spartalizumab + fluorouracil + leucovorin + oxaliplatin + docetaxel

This perioperative treatment regimen, evaluated in the GASPAR phase II clinical trial (NCT04736485), combines the anti-PD-1 monoclonal antibody spartalizumab (PDR001) with the FLOT chemotherapy backbone (fluorouracil, leucovorin, oxaliplatin, and docetaxel). Developed in collaboration with Centre François Baclesse, the regimen is designed for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. Spartalizumab functions as an immune checkpoint inhibitor by blocking the PD-1/PD-L1 pathway, thereby enhancing the T-cell mediated anti-tumor response. The FLOT component provides a potent cytotoxic effect through multiple mechanisms: fluorouracil inhibits thymidylate synthase, oxaliplatin induces DNA cross-linking, and docetaxel stabilizes microtubules to prevent cell division. The treatment is administered both before and after surgery to improve pathological complete regression rates and overall survival.

Other names

GASPAR regimenSpartalizumab + FLOT